Stockscreener 앱 받기
6.27
8.87%
-0.61
시간 외 거래:
6.38
0.11
+1.75%
전일 마감가:
$6.88
열려 있는:
$6.9
하루 거래량:
3.51M
Relative Volume:
1.20
시가총액:
$286.39M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-7.5542
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-15.10%
1개월 성능:
-24.09%
6개월 성능:
-55.41%
1년 성능:
+33.69%
1일 변동 폭
$6.19
$6.966
1주일 범위
$6.19
$7.46
52주 변동 폭
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.27 | 337.55M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Securities Fraud and Market Volatility in Biotech: Lessons from Capricor's Downfall - AInvest
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025Capricor Therapeutics, Inc. (CAPR) - TradingView
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - WV News
Important Notice to Long-Term Shareholders of Capricor - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shareholders of Class Action Lawsuit and September 15, 2025 Deadline - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - StreetInsider
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Capricor Therapeutics, Inc.September 15, 2025 Deadline - ACCESS Newswire
What analysts say about Capricor Therapeutics Inc. stockTremendous return on equity - PrintWeekIndia
Capricor Therapeutics Inc. Stock Analysis and ForecastHigh-octane investment gains - Jammu Links News
Is Capricor Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
What drives Capricor Therapeutics Inc. stock priceExceptional trading performance - jammulinksnews.com
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: - GlobeNewswire
Investor Sues Biotech Capricor After Product's FDA Denial - Law360
Levi & Korsinsky Urges Capricor Therapeutics, Inc. (CAPR) Shareholders to Act Before Lead Plaintiff Deadline September 15, 2025 - ACCESS Newswire
Capricor Investor Sues After Disappointing FDA Return on Therapy - Bloomberg Law News
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - TradingView
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Will Capricor Therapeutics Inc. stock split in the near futureInvestor Favorite Picks - Newser
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewswire
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors - TradingView
Capricor’s Trial Data Deception Triggers Major Lawsuit - TipRanks
What analysts say about Capricor Therapeutics Inc. stock outlookPrecision Entry Strategy - Newser
Shareholders Filed a Lawsuit Against Capricor for Misleading Investors About FDA Approval - TradingView
Capricor Therapeutics ($CAPR) Regulatory Misrepresentations and Stock Collapse Case - TradingView
BREAKING: Capricor Therapeutics Sued For Securities Fraud; - GlobeNewswire
September 15, 2025 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Roth Capital Issues Pessimistic Forecast for CAPR Earnings - Defense World
Equities Analysts Offer Predictions for CAPR FY2025 Earnings - Defense World
Investigation Opened on Behalf of Capricor Therapeutics, Inc. (CAPR) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $24.67 Consensus PT from Brokerages - Defense World
Bragar Eagel & Squire, P.C. is Investigating Capricor - GlobeNewswire
Roth Capital Lowers Capricor Therapeutics (NASDAQ:CAPR) Price Target to $12.00 - MarketBeat
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Capricor Sinks After FDA Rejects Drug for Muscle Disease - MSN
How Capricor Therapeutics Inc. stock performs during market volatilityFree Access to Stock Community - Newser
What makes Capricor Therapeutics Inc. stock price move sharplyDaily Stock Radar - Newser
Why Capricor Therapeutics Inc. stock attracts strong analyst attentionSteady Profit Stock Forecasts - Newser
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):